Results 251 to 260 of about 224,997 (329)

Multicohort Validation of Gut Microbiome Signatures for Cholangiocarcinoma Diagnosis and Functional Characterization of Bifidobacterium Pseudocatenulatum

open access: yesAdvanced Science, Volume 13, Issue 27, 13 May 2026.
This study analyzes gut bacteria in cholangiocarcinoma patients, revealing distinct microbial signatures that enable accurate disease detection. Species‐based diagnostic models achieved over 98% accuracy in identifying cholangiocarcinoma and distinguished it from other liver diseases. The research demonstrates that specific beneficial bacteria suppress
Benchen Rao   +18 more
wiley   +1 more source

Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation

open access: yesAdvanced Science, Volume 13, Issue 26, 8 May 2026.
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy   +8 more
wiley   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath   +2 more
wiley   +1 more source

Impact of Underlying Liver Disease on the Risk and Prognostic Factors of Breast Cancer Liver Metastases: A Retrospective Multicenter Cohort Study

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective To examine factors influencing breast cancer liver metastases (BCLM) and assess the impact of underlying liver diseases (nonalcoholic fatty liver and HBsAg infection) on BCLM development. Methods Patients diagnosed with breast cancer at four affiliated hospitals in China between 2014 and 2024 were included.
Xiaowen Wang   +16 more
wiley   +1 more source

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy